Our leadership team combine biotech and pharma expertise in immuno-oncology, clinical and corporate strategy to manage the activities of iTeos both in Europe and USA in order to develop and deliver the next generation of cancer immunotherapies.

We have built a Board composed of the different talents to support the growth and differentiation of iTeos as a leader in development of the next generation of cancer immunotherapies by combining expertise in immuno-oncology, clinical strategy, company builders, corporate strategy, finance and commercialization.